Nano-strategies targeting the integrin αvβ3 network for cancer therapy

Tsai Mu Cheng, Wong Jin Chang, Hsiu Yi Chu, Roberto De Luca, Jens Z. Pedersen, Sandra Incerpi, Zi Lin Li, Ya Jung Shih, Hung Yun Lin, Kuan Wang, Jacqueline Whang-Peng

Research output: Contribution to journalReview articlepeer-review

29 Citations (Scopus)


Integrin αvβ3, a cell surface receptor, participates in signaling transduction pathways in cancer cell proliferation and metastasis. Several ligands bind to integrin αvβ3 to regulate proliferation and metastasis in cancer cells. Crosstalk between the integrin and other signal transduction pathways also plays an important role in modulating cancer proliferation. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) activates the downstream integrin FAK to stimulate biological activities including cancer proliferation and metastasis. Blockage of signals related to integrin αvβ3 was shown to be a promising target for cancer therapies. 3,3,5,5-tetraiodothyroacetic acid (tetrac) completely binds to the integrin with the thyroid hormone to suppress cancer proliferation. The (E)-stilbene analog, resveratrol, also binds to integrin αvβ3 to inhibit cancer growth. Recently, nanotechnologies have been used in the biomedical field for detection and therapeutic purposes. In the current review, we show and evaluate the potentiation of the nanomaterial carrier RGD peptide, derivatives of PLGA-tetrac (NDAT), and nanoresveratrol targeting integrin αvβ3 in cancer therapies.

Original languageEnglish
Article number1684
Issue number7
Publication statusPublished - Jul 2021


  • Drug-delivery system
  • Integrin αvβ3
  • Nanomaterial
  • NDAT
  • Resveratrol
  • RGD

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Nano-strategies targeting the integrin αvβ3 network for cancer therapy'. Together they form a unique fingerprint.

Cite this